These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22835495)

  • 1. High-density lipoproteins after acute coronary syndromes: evaluation of residual risk.
    Fácila L; Núñez J; Sanchis J; Cordero A; Fabregat-Andrés O; Morell S
    Rev Esp Cardiol (Engl Ed); 2013 Jan; 66(1):65-6. PubMed ID: 22835495
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes.
    Roe MT; Ou FS; Alexander KP; Newby LK; Foody JM; Gibler WB; Boden WE; Ohman EM; Smith SC; Peterson ED
    Eur Heart J; 2008 Oct; 29(20):2480-8. PubMed ID: 18716006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between HDL particles size and myeloperoxidase/ paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome.
    Emami Razavi A; Basati G; Varshosaz J; Abdi S
    Acta Med Iran; 2013 Jul; 51(6):365-71. PubMed ID: 23852840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome.
    Waksman R; Torguson R; Kent KM; Pichard AD; Suddath WO; Satler LF; Martin BD; Perlman TJ; Maltais JA; Weissman NJ; Fitzgerald PJ; Brewer HB
    J Am Coll Cardiol; 2010 Jun; 55(24):2727-35. PubMed ID: 20538165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy.
    Tselepis AD; Tsoumani ME; Kalantzi KI; Dimitriou AA; Tellis CC; Goudevenos IA
    J Thromb Haemost; 2011 Dec; 9(12):2371-8. PubMed ID: 22008470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome].
    Millán Núñez-Cortés J; Montoya JP; Salas XP; Hernández Mijares A; Carey VJ; Hermans MP; Sacks FM; Fruchart JC
    Endocrinol Nutr; 2011 Jan; 58(1):38-47. PubMed ID: 21208833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman.
    Al-Zakwani I; Sulaiman K; Al-Rasadi K; Mikhailidis DP
    Curr Med Res Opin; 2011 Apr; 27(4):879-85. PubMed ID: 21332274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endotoxin levels are associated with high-density lipoprotein, triglycerides, and troponin in patients with acute coronary syndrome and angina: possible contributions from periodontal sources.
    Goteiner D; Craig RG; Ashmen R; Janal MN; Eskin B; Lehrman N
    J Periodontol; 2008 Dec; 79(12):2331-9. PubMed ID: 19053924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Thromb Haemost; 2010 Aug; 104(2):279-86. PubMed ID: 20508896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
    Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstituted HDL in acute coronary syndromes.
    Chenevard R; Hürlimann D; Spieker L; Béchir M; Enseleit F; Hermann M; Flammer AJ; Sudano I; Corti R; Lüscher TF; Noll G; Ruschitzka F
    Cardiovasc Ther; 2012 Apr; 30(2):e51-7. PubMed ID: 20840194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
    Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction.
    Raposeiras Roubín S; Barreiro Pardal C; Roubín-Camiña F; Ocaranza Sanchez R; Alvarez Castro E; Paradela Dobarro B; García-Acuña JM; Aguiar Souto P; Jacquet Hervet M; Castromán MJ; Arufe I; Outes B; Reino-Maceiras MV; Abu Assi E; González-Juanatey JR
    Rev Port Cardiol; 2013 Feb; 32(2):117-22. PubMed ID: 23337430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood urea nitrogen and creatinine levels at admission for mortality risk assessment in patients with acute coronary syndromes.
    Saygitov RT; Glezer MG; Semakina SV
    Emerg Med J; 2010 Feb; 27(2):105-9. PubMed ID: 20156860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment.
    Riedel M; Lafitte M; Pucheu Y; Latry K; Couffinhal T
    Eur J Prev Cardiol; 2012 Oct; 19(5):1128-37. PubMed ID: 21900366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease.
    Medi C; Chew DP; Amerena J; Coverdale S; Soman A; Astley C; Rankin J; Brieger D
    Intern Med J; 2011 Oct; 41(10):743-50. PubMed ID: 21040324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.